Roberto Delpini

IRCCS Ospedale San Raffaele

Papers

1

Total Citations

14

H-Index

1

About

Roberto Delpini is a leading surgical oncologist whose research focuses on optimizing treatment protocols for rectal cancer, particularly the timing of minimally-invasive surgery following neoadjuvant chemoradiotherapy. His most notable contribution is the TiMiSNAR trial, a multicenter randomized controlled study that compared standard 8-week versus prolonged 12-week intervals to surgery after chemoradiation. This work addresses a critical controversy in colorectal oncology—whether extended waiting periods allow for more complete tumor regression before surgical intervention. With 14 citations, this landmark study has shaped clinical decision-making by providing high-quality evidence on surgical timing. Delpini’s research bridges the gap between retrospective observations of slow tumor regression and prospective validation, offering actionable insights for improving patient outcomes. His work demonstrates a commitment to rigorous trial design and translational impact, making him a key figure in advancing personalized surgical strategies for rectal cancer.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)
14 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 36
🏛 Institutions: IRCCS Ospedale San Raffaele

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago